Claims for Patent: 11,998,526

Summary for Patent: 11,998,526

Title:	Methods of improving renal function
Abstract:	Provided herein are methods of improving kidney function in a subject in need thereof.
Inventor(s):	Philip Thomas Frohlich, Andrew James KING, Chidambaram Ramachandran, Sarah Beth Noonberg
Assignee:	Chinook Therapeutics Inc
Application Number:	US18/223,340
Patent Claims:	1. A method of decreasing the occurrence of hematuria in a subject having biopsy-diagnosed IgA nephropathy, the method comprising administering to the subject from about 0.20 mg to about 1.5 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the hematuria is microhematuria, gross hematuria, symptomatic hematuria, or asymptomatic hematuria. 3. The method of claim 1, comprising administering to the subject from about 0.40 mg to about 0.85 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 4. The method of claim 3, comprising administering to the subject about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 5. The method of claim 1, wherein atrasentan is administered as atrasentan mandelate or atrasentan hydrochloride. 6. The method of claim 1, wherein the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, or acute kidney failure. 7. A method of reducing IgA-immune complex deposition in a kidney of a subject in need thereof, comprising administering to the subject from about mg to about 1.5 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 8. The method of claim 7, comprising a reduction in IgA-immune complexes in serum or urine of the subject, or in a kidney biopsy sample from the subject. 9. The method of claim 7, comprising a reduction in autoantibodies specific for galactose-deficient IgA in serum of the subject. 10. The method of claim 7, comprising administering to the subject from about 0.40 mg to about 0.85 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 11. The method of claim 10, comprising administering to the subject about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 12. The method of claim 7, wherein atrasentan is administered as atrasentan mandelate or atrasentan hydrochloride. 13. The method of claim 7, wherein the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, or acute kidney failure. 14. The method of claim 1, wherein the subject is concomitantly receiving a SGLT-2 inhibitor. 15. The method of claim 1, wherein the subject is concomitantly receiving an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), or a combination thereof. 16. The method of claim 1, wherein the subject has a proteinuria of at least about 1 g/day in at least two of three consecutive readings over the year prior to administering atrasentan, or a pharmaceutically acceptable salt thereof. 17. The method of claim 1, wherein the subject has an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m2 prior to administering atrasentan, or the pharmaceutically acceptable salt thereof. 18. The method of claim 1, comprising administering to the subject a dose of about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, once per day. 19. The method of claim 1, comprising administering to the subject a dosage form comprising about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein the dosage form is a tablet. 20. The method of claim 1, wherein atrasentan is administered as atrasentan monohydrochloride. 21. The method of claim 1, wherein atrasentan, or a pharmaceutically acceptable salt thereof, is administered in one or more polymorphic forms characterized, when measured at about 25° C. with Cu-Kα radiation, by an X-ray powder diffraction pattern comprising: (i) at least three peaks having respective values of about 8,3°, 9,7°, 10,0°, 13,0°, 17.2° or 19,5° and essentially without peaks having 20 values below about 6.2° and/or between about 6.6° and 8.0°; and/or (ii) peaks having respective values of about 6.7° and 22.05° and at least one peak having a respective value of about 8.4°, 15.6°, 18.0°, 18.5°, 19.8° or 20.6°; and/or (iii) peaks having respective values of about 6.7° and 21.95° and at least one peak having a respective 20 value of about 8.4°, 15.6°, 18.0°, 18.5°, 19.8° or 20.6°. 22. The method of claim 7, wherein the subject is concomitantly receiving a SGLT-2 inhibitor. 23. The method of claim 7, wherein the subject is concomitantly receiving an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), or a combination thereof. 24. The method of claim 7, wherein the subject has a proteinuria of at least about 1 g/day in at least two of three consecutive readings over the year prior to administering atrasentan, or a pharmaceutically acceptable salt thereof. 25. The method of claim 7, wherein the subject has an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m2 prior to administering atrasentan, or the pharmaceutically acceptable salt thereof. 26. The method of claim 7, comprising administering to the subject a dose of about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, once per day. 27. The method of claim 7, comprising administering to the subject a dosage form comprising about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein the dosage form is a tablet. 28. The method of claim 7, wherein atrasentan is administered as atrasentan monohydrochloride. 29. The method of claim 7, wherein atrasentan, or a pharmaceutically acceptable salt thereof, is administered in one or more polymorphic forms characterized, when measured at about 25° C. with Cu-Kα radiation, by an X-ray powder diffraction pattern comprising: (i) at least three peaks having respective 2-9, values of about 8,3°, 9.7°, 10,0°, 13,0°, 15,6°, 17.2° or 19,5° and essentially without peaks having 20 values below about 6,2° and/or between about 6.6° and 8.0°; and/or (ii) peaks having respective 2, values of about 6.7° and 22.05° and at least one peak having a respective 2-9, value of about 8.4°, 15.6°, 18.0°, 18.5°, 19.8° or 20.6°; and/or (iii) peaks having respective values of about 6.7° and 21.95° and at least one peak having a respective 20 value of about 8.4°, 15.6°, 18,0° 18.5°, 19,8° or 20.6°.